Determining patient's coagulation profile, ie detecting a bleeding tendency or the opposite, a
thrombotic risk, is crucial for clinicians in many situations. Routine coagulation assays and …

Monitoring factor VIII (FVIII) activity has traditionally been complicated by discrepancies
between assays for the various sorts of FVIII molecules. The advent of novel nonfactor …

Patients with severe hemophilia A (HA) have an increased risk of spontaneous and trauma‐
related bleeding because of a congenital absence of factor VIII (FVIII). Most severe HA …

Treatment of bleeding and thrombotic disorders is highly standardized and based on
evidence-based medicine guidelines. These evidence-based treatment schemes are well …

Background Heterogeneity in clinical bleeding phenotype has been observed in hemophilia
patients with similar FVIII or FIX activity levels. Thrombin generation and plasmin generation …

Thrombin plays an essential role in achieving and maintaining effective hemostasis and
stable clot formation. In people with hemophilia, deficiency of procoagulant factor (F) VIII or …

Background Clinical severity of hemophilia A (HA) varies, possibly due to interplay of many
factors in the hemostatic pathway. Pharmacokinetic monitoring of factor VIII (FVIII) …

Background The current study aims to identify the relationships between coagulation factors
and plasma thrombin generation in a large population-based study by comparing …

Laboratories monitor hemophilia replacement therapy by specific coagulation factor
measurement before and after the infusion of human-derived or recombinant factors …

This study was conducted to assess the levels of inflammatory factors and angiogenic
factors in patients with severe hemophilia A and evaluate their diagnostic values for acute …